Site article, page-56

Thanks for all your input, it's interesting to hear some outside perspectives. But attention to detail. I still think you are quite confused about the market Anteo is targeting if you are quoting a device with a limit of detection in the ng/mL region. Wrong market.

Any man and his dog can make a standard sensitivity troponin test. High sensitvity tests are a different game, and there are a limited number of tests in this area. I know which one looks by far the best to me. The minicare. And the publications surroundingthis device suggest they are looking for a new surface chemistry after many years of optimisation, they still find that >95% of their antibodies are nonfunctional in the best of cases. Anteo's technology is required here imo.